Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations

Leukemia. 2024 Apr 13. doi: 10.1038/s41375-024-02248-0. Online ahead of print.

Nikola Curik^#^{1

2}, Adam Laznicka^#^{1

2

3}, Vaclava Polivkova¹, Jitka Krizkova¹, Eva Pokorna², Pavel Semerak¹, Pavla Suchankova¹, Pavel Burda^{1

2}, Andreas Hochhaus⁴, Katerina Machova Polakova^{5

6}

¹ Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
² Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
³ Second Faculty of Medicine, Charles University, Prague, Czech Republic.
⁴ Abteilung Hämatologie/Onkologie, Klinik für Innere Medizin II, University of Jena, Jena, Germany.
⁵ Institute of Hematology and Blood Transfusion, Prague, Czech Republic. Katerina.Machova@uhkt.cz.
⁶ Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic. Katerina.Machova@uhkt.cz.

^# Contributed equally.

No abstract available

Grants and funding